Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761170
Company: GENENTECH INC
Company: GENENTECH INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| PHESGO | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 1,200MG;600MG;30,000UNITS | INJECTABLE;SUBCUTANEOUS | Prescription | None | No | No |
| PHESGO | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 600MG;600MG;20,000UNITS | INJECTABLE;SUBCUTANEOUS | Prescription | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 06/29/2020 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761170Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761170Orig1s000TOC.html |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 05/18/2026 | SUPPL-16 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761170s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761170Orig1s016ltr.pdf | |
| 11/22/2024 | SUPPL-7 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761170s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761170Orig1s007ltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 05/18/2026 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761170s016lbl.pdf | |
| 11/22/2024 | SUPPL-7 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761170s007lbl.pdf | |
| 06/29/2020 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf |